FindTrial
Sign In

The study of radionuclide imaging and biomarkers in clinical diagnosis and treatment of Parkinson's disease

The study of radionuclide imaging and biomarkers in clinical diagnosis and treatment of Parkinson's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DOC-16008645
Enrollment
Unknown
Registered
2016-06-15
Start date
2016-07-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Interventions

Gold Standard:
Index test:

Sponsors

101th Hospital of PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: early stage PD, motor-complictions PD

Exclusion criteria

Exclusion criteria: secondery PD

Design outcomes

Primary

MeasureTime frame
striatal-to-occipital ratio, SOR;PDRP value;—

Secondary

MeasureTime frame
UPDRSIII;Cognitive function, visual spatial ability, non verbal memory, attention, executive function test;—

Contacts

Public ContactLin Wei

101th Hospital of PLA

smithlinwx@aliyun.com+86 13812512187

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026